Sperduto et al. developed DS‐GPA to evaluate the prognosis of patients with BMs35; DS‐GPA is now used as a prognostic factor in an American Society for Radiation Oncology guideline for radiotherapeutic and surgical management for newly diagnosed BMs.36 For NSCLC, DS‐GPA consists of four prognostic factors, including age, KPS, extracranial metastases, and number of BMs. This evidence concerns the gene GYPA and non-small cell lung carcinoma.